Eastman R C, Gorden P, Glatstein E, Roth J
Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712.
Conventional megavoltage irradiation of GH-secreting tumors has predictable effects on tumor mass, GH, and pituitary function. 1. Further growth of the tumor is prevented in more than 99% of patients, with only a fraction of a percent of patients requiring subsequent surgery for tumor mass effects. 2. GH falls predictably with time. By 2 years GH falls by about 50% from the baseline level, and by 5 years by about 75% from the baseline level. The initial GH elevation and the size and erosive features of the sella turcica do not affect the percent decrease in GH from the baseline elevation. 3. With prolonged follow-up, further decrease in GH is seen at 10 and 15 years, with the fraction of surviving patients achieving GH levels less than 5 ng/mL approaching 90% after 15 years in our experience. Gender, previous surgery, and hyperprolactinemia do not seem to affect the response to treatment. Patients with initial GH greater than 100 ng/mL are significantly less likely to achieve GH values less than 5 ng/mL during long-term follow-up. 4. Hypopituitarism is a predictable outcome of treatment, is delayed, and may be more likely in patients who have had surgery prior to irradiation. There is no evidence that this complication is more common in patients with acromegaly than in patients with other pituitary adenomas receiving similar treatment. 5. Vision loss due to megavoltage irradiation--using modern techniques and limiting the total dose to 4680 rad given in 25 fractions over 35 days, with individual fractions not exceeding 180 rad--is extremely rare. The reported cases have occurred almost entirely in patients who have received larger doses or higher fractional doses. The theory that patients with acromegaly are prone to radiation-induced injury to the CNS and optic nerves and chiasm because of small vessel disease is not supported by a review of the reported cases. 6. Brain necrosis and secondary neoplasms induced by irradiation are extremely rare. 7. Although anecdotal evidence raises the question of changes in intellectual function following irradiation, this has not been studied in adults receiving pituitary irradiation.
对分泌生长激素的肿瘤进行传统的兆伏级放疗,对肿瘤体积、生长激素及垂体功能会产生可预测的影响。1. 在超过99%的患者中,肿瘤的进一步生长得到抑制,只有极小部分患者因肿瘤体积效应需要后续手术治疗。2. 生长激素水平会随时间呈可预测性下降。到2年时,生长激素水平较基线水平下降约50%,到5年时较基线水平下降约75%。初始生长激素升高水平以及蝶鞍的大小和侵蚀特征并不影响生长激素从基线升高水平下降的百分比。3. 随着随访时间延长,在10年和15年时生长激素水平进一步下降,根据我们的经验,15年后存活患者中生长激素水平低于5 ng/mL的比例接近90%。性别、既往手术史及高泌乳素血症似乎并不影响治疗反应。初始生长激素水平大于100 ng/mL的患者在长期随访期间达到生长激素水平低于5 ng/mL的可能性显著降低。4. 垂体功能减退是治疗的可预测结果,出现时间较晚,并且在放疗前接受过手术的患者中可能更易发生。没有证据表明这种并发症在肢端肥大症患者中比接受类似治疗的其他垂体腺瘤患者更常见。5. 使用现代技术并将总剂量限制在35天内分25次给予4680拉德,单次剂量不超过180拉德,因兆伏级放疗导致的视力丧失极为罕见。报告的病例几乎都发生在接受了更大剂量或更高分次剂量的患者中。肢端肥大症患者因小血管疾病而易于发生放疗诱导的中枢神经系统、视神经及视交叉损伤这一理论,在对报告病例的回顾中未得到支持。6. 放疗诱发的脑坏死和继发性肿瘤极为罕见。7. 尽管有轶事证据提出了放疗后智力功能变化的问题,但这在接受垂体放疗的成年人中尚未得到研究。